CA3141998A1 - Pharmacological agents for treating protein aggregation diseases of the eye - Google Patents

Pharmacological agents for treating protein aggregation diseases of the eye Download PDF

Info

Publication number
CA3141998A1
CA3141998A1 CA3141998A CA3141998A CA3141998A1 CA 3141998 A1 CA3141998 A1 CA 3141998A1 CA 3141998 A CA3141998 A CA 3141998A CA 3141998 A CA3141998 A CA 3141998A CA 3141998 A1 CA3141998 A1 CA 3141998A1
Authority
CA
Canada
Prior art keywords
alkyl
cap4349
acid
hydrogen
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141998A
Other languages
English (en)
French (fr)
Inventor
Sridhar Govinda PRASAD
Marshall Clarke PETERMAN
Santosh Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plex Pharmaceuticals Inc
Original Assignee
Plex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plex Pharmaceuticals Inc filed Critical Plex Pharmaceuticals Inc
Publication of CA3141998A1 publication Critical patent/CA3141998A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3141998A 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye Pending CA3141998A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
US62/855,560 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (1)

Publication Number Publication Date
CA3141998A1 true CA3141998A1 (en) 2020-12-03

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141998A Pending CA3141998A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Country Status (8)

Country Link
US (1) US20220241247A1 (https=)
EP (1) EP3976017A4 (https=)
JP (1) JP2022534420A (https=)
CN (1) CN114173771A (https=)
BR (1) BR112021024151A2 (https=)
CA (1) CA3141998A1 (https=)
MX (1) MX2021014682A (https=)
WO (1) WO2020243720A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4097092A1 (en) * 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20250019352A1 (en) * 2021-06-29 2025-01-16 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113523A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
RU2586330C2 (ru) * 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
RU2015138891A (ru) * 2013-03-08 2017-04-11 Аллерган, Инк. Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами
PE20151747A1 (es) * 2013-03-14 2015-12-18 Univ Massachusetts Metodo para inhibir cataratas y presbicia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Also Published As

Publication number Publication date
JP2022534420A (ja) 2022-07-29
CN114173771A (zh) 2022-03-11
US20220241247A1 (en) 2022-08-04
BR112021024151A2 (pt) 2022-02-08
MX2021014682A (es) 2022-04-06
WO2020243720A9 (en) 2021-02-04
WO2020243720A1 (en) 2020-12-03
EP3976017A4 (en) 2023-06-14
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
JP4234430B2 (ja) チオールを含むｎａａｌａｄアーゼ抑制物質
JP7532259B2 (ja) 眼疾患治療薬剤
AU2017317529A1 (en) Aldehyde trapping compounds and methods of use thereof
AU2017317524A1 (en) Aldehyde trapping compounds and uses thereof
CA3141998A1 (en) Pharmacological agents for treating protein aggregation diseases of the eye
TW201444860A (zh) 脲嘧啶核苷衍生物、組合物及使用方法
EP1043322B1 (en) Vitamin e derivatives
WO2017112947A1 (en) Cftr regulators and methods of use thereof
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
WO2020213693A1 (ja) リポ酸プロドラッグ
KR980008226A (ko) 시각기능장애의 예방 및 치료제
EP4501918A1 (en) 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient
TW201625264A (zh) 水晶體硬化抑制劑
US7511036B2 (en) Dihydrothiazine prodrugs of thiazolium agents
US11939324B2 (en) Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
KR20140082699A (ko) 플라빈 아데닌 디뉴클레오티드 또는 그의 염을 유효 성분으로서 함유하는 각막상피세포사의 억제제
JP2010235535A (ja) ＰＰＡＲαアゴニストを有効成分として含有する網脈絡膜疾患の予防又は治療剤
KR20260015836A (ko) 노안 치료용 시스테인 유도체
TW202330510A (zh) 對老花眼等之治療或預防有用之含硫化合物
JP3496111B2 (ja) 涙液分泌促進および角結膜障害治療剤
HK40050888A (en) Pharmacological agents for treating ocular diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240603

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250528

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251117

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119